Stryker Co. (NYSE:SYK) Position Boosted by Capital Asset Advisory Services LLC

Capital Asset Advisory Services LLC boosted its position in Stryker Co. (NYSE:SYK) by 3.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,277 shares of the medical technology company’s stock after purchasing an additional 41 shares during the period. Capital Asset Advisory Services LLC’s holdings in Stryker were worth $448,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of SYK. Harbor Investment Advisory LLC boosted its holdings in shares of Stryker by 0.4% during the 1st quarter. Harbor Investment Advisory LLC now owns 6,982 shares of the medical technology company’s stock worth $2,499,000 after buying an additional 31 shares during the period. Bremer Bank National Association boosted its holdings in Stryker by 4.0% during the fourth quarter. Bremer Bank National Association now owns 888 shares of the medical technology company’s stock valued at $266,000 after acquiring an additional 34 shares during the period. Simon Quick Advisors LLC grew its position in shares of Stryker by 3.0% in the fourth quarter. Simon Quick Advisors LLC now owns 1,158 shares of the medical technology company’s stock valued at $347,000 after purchasing an additional 34 shares during the last quarter. Consolidated Portfolio Review Corp increased its stake in shares of Stryker by 3.6% in the fourth quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company’s stock worth $294,000 after purchasing an additional 34 shares during the period. Finally, FourThought Financial Partners LLC lifted its position in shares of Stryker by 3.3% during the 4th quarter. FourThought Financial Partners LLC now owns 1,076 shares of the medical technology company’s stock worth $322,000 after purchasing an additional 34 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

SYK stock traded down $0.11 during mid-day trading on Friday, hitting $340.43. The stock had a trading volume of 1,894,420 shares, compared to its average volume of 1,315,695. The company has a current ratio of 1.71, a quick ratio of 0.99 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $129.69 billion, a P/E ratio of 38.86, a P/E/G ratio of 2.68 and a beta of 0.92. The firm has a fifty day simple moving average of $337.38 and a 200 day simple moving average of $333.39. Stryker Co. has a 52 week low of $249.98 and a 52 week high of $361.41.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share for the quarter, topping the consensus estimate of $2.36 by $0.14. Stryker had a return on equity of 23.05% and a net margin of 16.03%. The firm had revenue of $5.24 billion during the quarter, compared to analysts’ expectations of $5.10 billion. During the same period in the prior year, the company earned $2.14 earnings per share. The company’s quarterly revenue was up 9.7% on a year-over-year basis. As a group, research analysts forecast that Stryker Co. will post 11.95 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Friday, June 28th will be given a $0.80 dividend. The ex-dividend date is Friday, June 28th. This represents a $3.20 dividend on an annualized basis and a yield of 0.94%. Stryker’s dividend payout ratio is currently 36.53%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Wells Fargo & Company lifted their price target on Stryker from $364.00 to $381.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Citigroup increased their price target on shares of Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Robert W. Baird raised their price objective on shares of Stryker from $367.00 to $378.00 and gave the stock an “outperform” rating in a report on Wednesday, May 1st. UBS Group upped their target price on shares of Stryker from $339.00 to $351.00 and gave the stock a “neutral” rating in a report on Wednesday, May 1st. Finally, Royal Bank of Canada lifted their target price on Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a research note on Monday, April 15th. Four equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $370.58.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.